Xtl Biopharmaceuticals (XTLB) Common Equity (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Common Equity for 17 consecutive years, with -$254000.0 the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 104.67% year-over-year to -$254000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$254000.0 (down 104.67% YoY) and the FY2025 annual result came in at -$254000.0, down 104.67% from the prior year.
• Common Equity fell to -$254000.0 in Q4 2025 per XTLB's latest filing, from -$47000.0 in the prior quarter.
• Over the last five years, Common Equity for XTLB reached as high as $5.8 million in Q1 2022 and fell as low as -$254000.0 in Q4 2025.
• A 5-year average of $3.5 million and a median of $3.2 million in 2021 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity surged 144.82% — and 2025, when it tumbled 104.67%.
• Year by year, Common Equity stood at $5.3 million in 2021, then slipped by 25.01% to $4.0 million in 2022, then slumped by 44.49% to $2.2 million in 2023, then jumped by 144.82% to $5.4 million in 2024, then tumbled by 104.67% to -$254000.0 in 2025.
• According to Business Quant data, Common Equity over the past three periods registered -$254000.0, -$47000.0, and $5.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.